Fundraising FoxNuvig Therapeutics
14 known investors
Find your way into Nuvig Therapeutics
Sign up to find every way you can get introduced to Nuvig Therapeutics
- Your email: who you already know at Nuvig Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nuvig Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function. It targets patients with autoimmune conditions.
Investors · 14
How we know: Sanofi Ventures's portfolio page · funding news · nuvigtx.com · Not right? Tell us
How we know: nuvigtx.com · Not right? Tell us
How we know: nuvigtx.com · Not right? Tell us
How we know: nuvigtx.com · Not right? Tell us
How we know: nuvigtx.com · Not right? Tell us
How we know: funding news · nuvigtx.com · Not right? Tell us
How we know: funding news · nuvigtx.com · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$161M disclosed across 1 of 2 rounds · 2022–2024
- $161MSeries BDec 2024 · 2 sources
Blue Owl Healthcare Opportunities (lead), Norwest Venture Partners (lead), Sanofi Ventures (lead), abrdn Inc., Alexandria Venture Investments, B Capital, Bristol Myers Squibb, Digitalis Ventures, Global BioAccess Fund, Leaps by Bayer, LOTTE Holdings, Mission BioCapital, Novo Holdings A/S, Platanus
Source ↗ - Undisclosed amountSeries AMay 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Nuvig Therapeutics do?
- Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function. It targets patients with autoimmune conditions.
- Who are Nuvig Therapeutics's investors?
- Nuvig Therapeutics's investors include Sanofi Ventures, abrdn plc, Alexandria, B Capital, Digitalis Ventures, Global BioAccess Fund, Leaps by Bayer, Mission Biocapital and 3 more.
- How much funding has Nuvig Therapeutics raised?
- Nuvig Therapeutics has disclosed $161M raised across 1 of its 2 known rounds.